Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy

Erwin S. Schultz, Beatrice Schuler-Thurner, Vincent Stroobant, Lars Jenne, Thomas G. Berger, Kris Thielemanns, Pierre van der Bruggen and Gerold Schuler
J Immunol January 15, 2004, 172 (2) 1304-1310; DOI: https://doi.org/10.4049/jimmunol.172.2.1304

Abstract

Recently, we have demonstrated that tumor-specific CD4+ Th cell responses can be rapidly induced in advanced melanoma patients by vaccination with peptide-loaded monocyte-derived dendritic cells. Most patients showed a T cell reactivity against a melanoma Ag 3 (MAGE-3) peptide (MAGE-3243–258), which has been previously found to be presented by HLA-DP4 molecules. To analyze the functional and specificity profile of this in vivo T cell response in detail, peptide-specific CD4+ T cell clones were established from postvaccination blood samples of two HLA-DP4 patients. These T cell clones recognized not only peptide-loaded stimulator cells but also dendritic cells loaded with a recombinant MAGE-3 protein, demonstrating that these T cells were directed against a naturally processed MAGE-3 epitope. The isolated CD4+ Th cells showed a typical Th1 cytokine profile upon stimulation. From the first patient several CD4+ T cell clones recognizing the antigenic peptide used for vaccination in the context of HLA-DP4 were obtained, whereas we have isolated from the second patient CD4+ T cell clones which were restricted by HLA-DQB1*0604. Analyzing a panel of truncated peptides revealed that the CD4+ T cell clones recognized different core epitopes within the original peptide used for vaccination. Importantly, a DP4-restricted T cell clone was stimulated by dendritic cells loaded with apoptotic or necrotic tumor cells and even directly recognized HLA class II- and MAGE-3-expressing tumor cells. Moreover, these T cells exhibited cytolytic activity involving Fas-Fas ligand interactions. These findings support that vaccination-induced CD4+ Th cells might play an important functional role in antitumor immunity.

The identification of genes encoding Ags recognized by CD8+ cytolytic T lymphocytes on human tumor cells led to the development of new immunotherapeutic strategies (1, 2). Many tumor-specific HLA class I peptides have been identified and used to immunize cancer patients. Induction of tumor-specific T cell responses and regression of metastases have been demonstrated in vaccinated patients but overall clinical response rates remain low (3, 4, 5, 6, 7). An optimal vaccination protocol should induce both tumor-specific CD8+ CTLs and CD4+ Th lymphocytes as several animal studies have shown that the latter play a critical role in inducing and maintaining antitumor immunity (8, 9, 10). Human tumor Ags recognized by CD4+ T cells are being identified with increasing frequency (1, 11). Most epitopes have been found to be presented by HLA-DR molecules. Recently, we described a melanoma Ag 3 (MAGE-3)3 peptide presented by HLA-DP4, a dominant HLA class II allele, expressed in ∼76% of Caucasians (12). In a clinical trial using autologous, monocyte-derived, mature dendritic cells (DCs) loaded with tumor-specific HLA class I- and II-binding peptides to vaccinate patients with metastatic melanoma, we could demonstrate a strong TH1 response against the MAGE-3.DP4 peptide in the majority of patients (13). To analyze the functional and specificity profile of this TH1 response in detail, peptide-specific CD4+ T cell clones from two vaccinated patients were established. These CD4+ T cell clones recognized not only peptide-loaded stimulator cells but also DCs loaded with a recombinant MAGE-3 protein demonstrating that they were MAGE-3 specific and not directed against a contaminant in the batch of peptide. Analyzing the HLA restriction revealed that CD4+ T cells obtained from the first patient recognized the antigenic peptide in the context of HLA-DP4 as expected, whereas CD4+ T cells obtained from the second patient were HLA-DQB1*0604 restricted, although the patient was HLA-DP4+. Using a panel of truncated peptides, we could demonstrate that the T cell clones derived from the two patients did not only differ in their HLA restriction but recognized different core epitopes located in the 16-mer peptide KKLLTQHFVQENYLEY (MAGE-3243–258) used for vaccination. Importantly, the MAGE-3-specific CD4+ T cells were stimulated by DCs that had taken up dead or dying tumor cells and even directly recognized HLA class II- and MAGE-3-expressing melanoma cells. The MAGE-3.DP4 peptide represents an ideal candidate for peptide-based vaccination strategies because it can be presented by different HLA class II molecules, is immunogenic in advanced cancer patients, and the induced Th1 cells can recognize naturally processed peptide on tumor cells.

Materials and Methods

Cell lines, reagents, and Abs

EBV-transformed B (EBV-B) cell lines and tumor cell lines were cultured in RPMI 1640 (BioWhittaker, Verviers, Belgium) supplemented with 10% FCS (PAA Laboratories, Linz, Austria), 20 μg/ml gentamicin (Sigma-Aldrich, Taufkirchen, Germany), 2 mM l-glutamine (BioWhittaker), 10 mM HEPES (Sigma-Aldrich), and 10 mM sodium pyruvate (Invitrogen, Paisley, U.K.). DCs and CD4+ T cells were cultured in the same medium supplemented with 1% autologous plasma or 10% human serum (BioWhittaker) instead of FCS, hereafter referred to as DC or T cell medium, respectively. Human IL-2, IL-4, and GM-CSF were purchased from Novartis (Nuremberg, Germany), IL-1β and IL-6 from Strathmann Biotech (Hamburg, Germany), IL-7 from Biomol (Hamburg, Germany), TNF-α from Bender (Vienna, Austria), and PGE2 from Pharmacia and Upjohn (Erlangen, Germany). The following mouse anti-human mAbs were used for flow cytometry or blocking experiments: anti-Fas (ZB4) and anti-HLA-DQ (SPVL3) from Immunotech (Marseille, France), anti-Fas ligand (FasL; 8B8) from Oncogene (Boston, MA), anti-TRAIL (75411.11) and anti-TNF-α (1825.121) from R&D Systems (Wiebaden, Germany), anti-CD3, anti-CD4, anti-CD95 (EOS9.1), and anti-perforin (δG9) from BD PharMingen (San Diego, CA), anti-HLA-DR (L243) and anti-HLA-DP (B7/21) from BD Biosciences (San Jose, CA), and isotype control Abs IgG1, IgG2a, and IgM from Cymbus Biotechnology (Chandlers Ford, U.K.). The polyclonal goat anti-mouse IgG+ IgM Ab was purchased from BD PharMingen.

Flow cytometric analysis

Analysis was performed using the BD Biosciences FACScan flow cytometer. In brief, cells were incubated with the appropriate concentration of Abs for 30 min at 4°C. Cells were then washed two times with PBS supplemented with 1% BSA and subsequently analyzed. In some cases, cells were incubated with a polyclonal FITC-labeled goat anti-mouse IgG/IgM Ab as second Ab. FasL expression analysis was performed on T cells activated for 2 h in the presence of 2.5 μg/ml PHA (PHA-P). For intracellular perforin expression analysis, lymphocytes were first fixed and permeabilized using the BD Cytofix/Cytoperm kit from BD PharMingen and subsequently stained with an FITC-conjugated anti-perforin Ab.

DCs and CD4+ responder T cells

DCs were generated from leukapheresis products from patients R12 and R15 essentially as described previously (14). Briefly, PBMC were obtained by Ficoll density gradient centrifugation and monocytes were isolated by plastic adherence and cultured in the presence of 800 U/ml GM-CSF and 500 U/ml IL-4 for 6 days to generate immature, monocyte-derived DCs. Maturation was induced by adding a cytokine mixture consisting of 10 ng/ml IL-1β, 100 U/ml IL-6, 10 ng/ml TNF-α, and 1 μg/ml PGE2 (15). Mature DCs were harvested on day 7. CD4+ T lymphocytes were isolated from postvaccination PBMC by negative selection using anti-CD8+, anti-CD14+, anti-CD19+, and anti-CD56+ mAbs coupled to magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).

Generation of peptide-specific CD4+ T cell clones

CD4+ T cells (1 × 106) were cocultured with 3 × 104 autologous peptide-loaded (10 μg/ml for 3 h) and irradiated (100 Gy) mature DCs in 24-well plates in 2 ml of T cell medium. On day 3, 50 U/ml IL-2 and 10 ng/ml IL-7 were added. On day 7, peptide-specific T cells were cloned by limiting dilution using irradiated autologous EBV-B cells loaded for 1 h with 10 μg/ml peptide (5 × 103–104 cells/round-bottom microwell) as stimulator cells. Irradiated allogeneic LG2-EBV (5 × 103–104 cells/well) were used as feeder cells. CD4+ T cell clones were restimulated once per week with irradiated peptide-loaded EBV-B cells in T cell medium supplemented with IL-2 (50 U/ml) and feeder cells. Growing T cell clones were tested for their capacity to produce IFN-γ when stimulated with autologous peptide-loaded EBV-B cells. IFN-γ was measured in the supernatants by ELISA using reagents from Medgenix Diagnostics-Biosource (Fleurus, Belgium).

Peptides

Peptides were synthesized by conventional solid-phase peptide synthesis using F-moc for transient NH2-terminal protection and were characterized using mass spectrometry. All peptides were >80% pure, as indicated by analytical HPLC. Lyophilized peptides were dissolved at 2 mg/ml in DMSO/acetic acid (10 mM) and stored at −20°C.

Recognition assay with protein-loaded DCs

Immature DCs were incubated for 48 h with 20 μg/ml of a recombinant MAGE-3 protein (kindly provided by GlaxoSmithKline, Rixensart, Belgium) or OVA (Sigma-Aldrich) in the presence of IL-4 and GM-CSF. The MAGE-3 protein is a fusion protein with a lipidated protein D derived from Haemopjilus influenzae at its N terminus and a sequence of several histidine residues at the C terminus of the protein (Prot.D MAGE-3/His). After 6 h, IL-1β, IL-6, TNF-α, and PGE2 were added to induce their maturation. CD4+ T cells (4 × 103/flat-bottom microwell) were stimulated with 15 × 103 protein-loaded DCs or peptide-loaded DCs (1 μM, 1 h) as a positive control and, after 20 h, IFN-γ released in the supernatant was measured by ELISA.

Recognition assay with peptides

CD4+ T cells (4 × 103/round-bottom microwell) were cocultured with 15 × 103 peptide-loaded EBV-B cells or DCs from different donors with known HLA class II typing. After 20 h, IFN-γ released in the supernatant was measured by ELISA. In some experiments, IL-4, IL-10, and TNF-α released in the supernatant were measured in addition. To identify the HLA restriction of the T cell clones, blocking of the Ag-induced production of IFN-γ was investigated using mAbs against HLA-DR, HLA-DQ, and HLA-DP. All mAbs were used at a final concentration of 10 μg/ml. To screen the set of truncated peptides, autologous EBV-B cells were incubated for 2 h in the presence of different peptides and different peptide concentrations.

Recognition assay with tumor cells

Several HLA-matched or -mismatched MAGE-3-expressing melanoma cell lines were seeded at 15 × 106/flat-bottom microwell and incubated for 48 h to allow the formation of a monolayer. CD4+ T cells were then added (at 4 × 103/microwell) and, after 20 h, IFN-γ secreted in the supernatants was measured by ELISA.

Recognition assay with dead or dying tumor cells

Briefly, 5 × 104 immature DCs were loaded with apoptotic or necrotic tumor cells at a ratio of 1:1 and cocultured in 200 μl of T cell medium in flat-bottom microwells. Necrotic tumor cell material was generated by repeated freeze-thaw cycles of 1 × 106 cells resuspended in 1 ml of RPMI 1640 medium. Apoptotic material was generated by irradiating tumor cells in 24 wells with 0.5–1.0 J/cm2 UVB (UV 3003 K; Waldmann Medizintechnik, Villingen-Schwenningen, Germany) which induced apoptosis within 8 h. Apoptosis was measured using an annexin V kit (BD PharMingen). Six hours later, IL-1β, IL-6, TNF-α, and PGE2 were added to induce maturation of the DCs. Forty-eight hours later, CD4+ T cells (5 × 104/microwell) were added to the microwells and, after 20 h, IFN-γ secreted in the supernatant was measured by ELISA.

Chromium release assay

Tumor cells were labeled with 100 μCi of Na51CrO4, loaded with peptide, washed, and preincubated for 30 min with the blocking anti-Fas Ab or isotype control at a concentration of 1 μg/ml before adding the responder cells at the indicated E:T ratios. Blocking Abs and isotype controls were present during the whole incubation step and chromium release was measured after incubation at 37°C for 4 h. For further blocking experiments, effector T cells were preincubated for 1 h in the presence of anti-TRAIL (50 ng/ml) or anti-TNF-α (100 ng/ml) Abs. Abs were also present during the 4-h incubation step.

Results

Generation of MAGE-3-specific CD4+ T cell clones

To analyze the functional and specificity profile of Th cell responses induced by vaccination with peptide-loaded DCs, CD4+ T cells were isolated from blood samples collected after the fifth vaccination of two patients who had previously shown strong TH1 reactions against peptide MAGE-3243–258 (13). CD4+ T cells from patients R12 and R15 were stimulated once in vitro with autologous peptide-loaded DCs. On day 7, peptide-specific CD4+ T cells were cloned by limiting dilution using autologous EBV-B cells loaded with peptide as stimulator cells and feeder cells. Growing T cell clones were tested for their ability to produce IFN-γ upon stimulation with autologous peptide-loaded EBV-B cells. Several peptide-specific CD4+ T cell clones were obtained from both patients. Additional experiments were conducted with CD4+ T cell clone 57 derived from patient R12 and CD4+ T cell clone 14 derived from patient R15, hereafter referred to as clone R12-57 and R15-14, respectively. It is noteworthy that peptide-specific Th cell clones could only be generated from postvaccination but not from prevaccination blood samples, underlining the efficacy of the vaccinations.

Importantly, the CD4+ T cell clones did not only recognize peptide-loaded DCs but also DCs loaded with a recombinant MAGE-3 protein demonstrating that these T cells were directed against a naturally processed MAGE-3 epitope (Fig. 1⇓).

FIGURE 1.
FIGURE 1.

CD4+ T cell clones R12-57 (A) and R14-15 (B) recognize a naturally processed MAGE-3 Ag. Autologous immature DCs were incubated for 48 h with 20 μg/ml MAGE-3 protein or OVA. Maturation of DCs was induced after 6 h by adding IL-1β, IL-6, TNF-γ, and PGE2. CD4+ T cells were cocultured with protein-loaded or peptide-loaded (1 μM) DCs and 20 h later IFN-γ secreted in the supernatant was measured by ELISA. Values shown are the means of triplicate determinations; bars, SD.

Determination of the HLA restriction of the CD4+ T cell clones

Since both patients were HLA-DPB1*0401+ and the MAGE-3 peptide has been previously shown to be presented by this HLA molecule, we assumed that the peptide-specific CD4+ T cell clones would be HLA-DP4 restricted. To analyze the HLA restriction of the clones, we tested whether monoclonal anti-DR, anti-DQ or anti-DP Abs would inhibit the recognition of APCs by the CD4+ T cells. As expected, recognition of autologous peptide-loaded EBV-B cells by clone R12-57 was completely abolished in the presence of anti-DP Abs, but not in the presence of anti-DR or anti-DQ Abs (Fig. 2⇓A). However, recognition of autologous peptide-loaded EBV-B cells by clone R15-14 was strongly inhibited in the presence of anti-DQ Abs (Fig. 2⇓B). Similar results were obtained with several other T cell clones derived from both patients (data not shown). To further determine the HLA restriction of the two clones several EBV-B cell lines with known HLA class II typing were tested for their ability to present the antigenic peptide to the different T cell clones. All of the EBV-B cell lines expressing HLA-DPB1*0401 were able to present the antigenic peptide to clone R12-57, whereas clone R15-14 only recognized peptide-loaded EBV-B cells expressing HLA-DQB1*0604 (Table I⇓).

FIGURE 2.
FIGURE 2.

HLA restriction analysis of CD4+ T cell clones R12-57 (A) and R14-15 (B). CD4+ T cells were stimulated with autologous peptide-loaded EBV-B cells (1 μM) in the presence or absence of anti-HLA-DR, -DQ, or -DP mAbs. Abs were tested for their capacity to inhibit IFN-γ production by the CD4+ T cells. Values shown are the mean of triplicate determinations; bars, SD.

View this table:
Table I.

Clone R12-57 and clone R15-14 recognize the antigenic peptide in the context of HLA-DPB1*0401 and HLA-DQB1*0604, respectively

Analysis of the core epitope recognized by the different CD4+ T cell clones

To test whether the two clones recognized different core epitopes of the 16-mer peptide KKLLTQHFVQENYLEY (MAGE-3243–258), we assayed the recognition of a set of truncated peptides. Truncation of either Q at the N terminus or L at the C terminus resulted in dramatic reduction or complete loss of recognition by the HLA-DQB1*0604-restricted clone R15-14. The DP4-restricted clone R12-57, however, only recognized peptides containing KLLTQHFVQENY as core sequence (Fig. 3⇓).

FIGURE 3.
FIGURE 3.

Fine specificity analysis of MAGE-3-specific CD4+ T cell clones using truncated peptides. IFN-γ production of CD4+ T cell clones R12-57 (A) and R15-14 (B) when stimulated with autologous EBV-B cells loaded with different truncated peptides derived from the 16-mer peptide KKLLTQHFVQENYLEY (MAGE-3243–258). Peptides were used at 2 μg/ml. Each column represents the mean of triplicate values; bars, SD.

The MAGE-3-specific CD4+ T cells show a TH1 cytokine profile

Because TH1 cells are thought to be advantageous in antitumor immunity, we analyzed the cytokine profile of the CD4+ T cell clones. Both clones showed a clear TH1 cytokine profile as they produced IFN-γ and TNF-α but no IL-4 or IL-10 upon stimulation with peptide-loaded DCs (Fig. 4⇓, data are shown for clone R12-57).

FIGURE 4.
FIGURE 4.

The MAGE-3-specific CD4+ T cells show a TH1 cytokine profile. CD4+ T cells were stimulated with autologous EBV-B cells loaded with peptide (1 μM) or not and after 20 h IFN-γ, TNF-α, IL-4, and IL-10 secreted in the supernatant was measured by ELISA. Values shown are the mean of triplicate determinations; bars, SD.

Recognition of DCs loaded with dead or dying tumor cells

To be relevant in vivo, tumor-specific Th cells should recognize Ags that are naturally processed and presented by APCs that have taken up dead or dying tumor cells. Therefore, we tested whether the CD4+ T cells were stimulated by DCs loaded with different preparations of tumor cells. As shown in Fig. 5⇓, clone R12-57 recognized HLA-DP4+ DCs loaded with apoptotic or necrotic HLA-mismatched MAGE-3+ melanoma cells, whereas viable, apoptotic, or necrotic HLA-DP4− MEL 397 melanoma cells alone were not able to stimulate the CD4+ T cell clone. In contrast, clone R12-57 was not stimulated by DCs loaded with apoptotic or necrotic BB 90 MEL cells, an uveal melanoma cell line that does not express MAGE-3. However, clone R15-14 did not show a significant recognition of DCs loaded with dead or dying tumor cells (data not shown). Because this finding could be due to a lower avidity of clone R15-14, we performed peptide titration analysis with both clones but there was no significant difference in peptide recognition (Fig. 6⇓).

FIGURE 5.
FIGURE 5.

CD4+ T cells specific for peptide MAGE-3243–258 are stimulated by DCs loaded with dead or dying tumor cells. DCs loaded with apoptotic or necrotic MAGE-3-expressing melanoma cells (MEL 397, HLA-DP4−) efficiently stimulate CD4+ T cell clone R12-57 to produce IFN-γ, whereas DCs loaded with apoptotic or necrotic MAGE-3− tumor cells (BB 90 MEL) do not. Values shown are the mean of triplicate determinations; bars, SD.

FIGURE 6.
FIGURE 6.

Peptide titration analysis. IFN-γ production of CD4+ T cell clones R12-57 (A) and R15-14 (B) when stimulated with autologous EBV-B cells loaded with different concentrations of peptide KKLLTQHFVQENYLEY (MAGE-3243–258).

Direct recognition of tumor cells

Since it has been shown that the MAGE-3.DP4 peptide is naturally expressed on tumor cells (12), we assayed the direct recognition of melanoma cell lines by the different CD4+ T cell clones (Fig. 7⇓). Clone R12-57 was stimulated to produce IFN-γ by melanoma cell lines expressing MAGE-3 and HLA-DP4, but did not recognize HLA-mismatched MAGE-3-expressing melanoma cell lines. However, clone R15-14 showed only minimal recognition of HLA-matched MAGE-3-expressing tumor cells using an ELISPOT assay (data not shown).

FIGURE 7.
FIGURE 7.

Direct recognition of tumor cells by MAGE-3-specific CD4+ T cells. IFN-γ production of clone R12-57 when stimulated by HLA-matched or -mismatched MAGE-3-expressing melanoma cell lines. Values shown are the mean of triplicate determinations; bars, SD.

Clone R12-57 lyses melanoma cells involving Fas-FasL interactions

Finally, we tested whether clone R12-57 showed cytolytic activity against MAGE-3- and HLA-DP4-expressing melanoma cell lines. In the absence of exogenous peptide, only poor lysis was observed (data not shown) but when loaded with low amounts of peptide (1 μM) the tumor cells were efficiently lysed (Fig. 8⇓A). The observed lysis was Ag specific as there was no lysis when loading the tumor cells with an irrelevant HLA-DP4-binding tetanus peptide (data not shown). In addition, lysis was strongly inhibited in the presence of a blocking anti-Fas Ab (Fig. 8⇓), whereas in the presence of anti-TRAIL or anti-TNF-α Abs only weak inhibition was observed (Fig. 8⇓B). Flow cytometric analysis demonstrated expression of Fas by the melanoma cell lines (Fig. 9⇓A) and expression of FasL but not perforin by the CD4+ T cell clone (Fig. 9⇓B).

FIGURE 8.
FIGURE 8.

Clone R12-57 lyses tumor cells involving Fas-FasL interactions. Melanoma cell lines SK-MEL 28 and MZ2-MEL (both expressing MAGE-3 and HLA-DP4) were labeled with 100 μCi of Na51CrO4, loaded with peptide, washed, and preincubated for 30 min with the anti-Fas mAb before adding to the responder cells at the indicated E:T ratios. Blocking mAbs and isotype control were present during the incubation step and chromium release was measured after incubation at 37°C for 4 h. Values shown are the mean of triplicate determinations; bars, SD.

FIGURE 9.
FIGURE 9.

Expression of Fas on the cell surface of melanoma cell lines (A) and expression of FasL and perforin by CD4+ T cell clone R1-57, respectively (B).

Discussion

We have previously shown that MAGE-3-specific CD4+ Th cells can be readily induced in advanced melanoma patients by vaccination with peptide-loaded, monocyte-derived DCs matured by a cytokine mixture (IL-1β, IL-6, TNF-α, and PGE2) which mimics monocyte-conditioned medium (13). In the present study, we analyzed the functional and specificity profile of these in vivo Th cell responses. Several Th cell clones recognizing peptide MAGE-3243–258 were generated from postvaccination blood samples of two immunized patients. The induced Th cells were shown to be TH1 cells, which are thought to be favorable in antitumor immunity. Recently, a disease-associated bias in TH1/TH2 responses against a defined tumor Ag has been demonstrated in patients with renal cell carcinoma or melanoma (16). In this study, the majority of patients with active disease were skewed toward TH2-type responses against MAGE-6-derived epitopes, whereas normal donors and patients with no current evidence of disease either showed mixed TH1/TH2 or strongly TH1-polarized responses, underlining the importance of antitumor TH1 responses.

Importantly, the CD4+ T cells recognized not only peptide-loaded DCs but as well DCs loaded with a recombinant MAGE-3 protein or (shown only for clone R12-57) apoptotic or necrotic tumor cell material. This finding implies a potential in vivo relevance of these vaccination-induced, tumor-specific Th cells as they should recognize DCs (and other APCs) at the tumor site that have taken up dead or dying tumor cells and further activate them via engagement of CD40 to allow for efficient CTL priming (9, 17, 18, 19). Beside providing help for the induction and maintenance of tumor-specific CTLs, CD4+ Th cells may also play a broader role in mediating activation of macrophages and eosinophils (20, 21). Furthermore, IFN-γ secreted by tumor-specific CD4+ T cells at the tumor site has been shown to be very important for tumor regression involving inhibition of tumor-induced angiogenesis (22). The MAGE-3-specific CD4+ T cells from patient R12 secreted IFN-γ upon stimulation with HLA-matched MAGE-3-expressing melanoma cells, demonstrating that direct recognition of tumor cells might be yet another antitumoral effector mechanism of these Th cells. Tumor-specific CD4+ Th cells have been even found to lyse HLA class II-expressing tumor cells (12, 23, 24, 25). In this study, clone R12-57 showed only poor lysis of HLA-matched tumor cells but this lysis was strongly enhanced in the presence of low amounts of exogenous peptide.

Different mechanisms by which CD4+ T cells exert their cytotoxicity have been described, including the perforin/granzyme pathway (26, 27, 28, 29), Fas-FasL interactions (30, 31, 32) and apoptosis induced by another member of the TNFR ligand family, TRAIL (33, 34). The latter was suggested to play an important role in the killing of melanoma cells by CD4+ T cells, while the tumor cells were resistant to apoptosis induced by FasL (33). In contrast to these findings, our data suggest that the MAGE-3/HLA-DP4-specific CD4+ T cells exerted their cytotoxicity via Fas-FasL interactions as the lysis of peptide-loaded melanoma cells was strongly inhibited in the presence of a blocking Ab against Fas, whereas only weak inhibition was observed in the presence of a blocking Ab against TRAIL or TNF-α. We believe that this discrepancy simply reflects the diversity of mechanisms that can be used by cytolytic CD4+ T cells. For instance, tumor-infiltrating CD4+ T cells have been shown to lyse autologous lung carcinoma cells via both perforin/granzyme- and TRAIL-mediated mechanisms (34). In addition, cytolytic CD4+ T cells specific for purified protein derivative of Mycobacterium tuberculosis have been shown to either use the perforin/granzyme or the Fas/FasL pathway depending on the kind of target cell (35). Some authors have argued that the observation of cytolytic activity in CD4+ T cells would be an in vitro artifact (36) but only recently cytolytic CD4+ T cells have been isolated ex vivo (26).

It is well known that class II peptides exist which can bind to different HLA molecules. This has been mainly reported for peptides binding to HLA-DR molecules and peptide-binding motifs largely shared by several common HLA-DR types have been identified (37). Recently, several promiscuous HLA-DR-restricted Th cell epitopes derived from tumor Ags such as HER2/neu, carcinoembryonic Ag, NY-ESO-1, and MAGE-3 have been described (24, 38, 39, 40, 41). In the present study, we could demonstrate that promiscuous binding of tumor-specific peptides does not only occur for HLA-DR molecules but also for other class II molecules as peptide MAGE-3243–258 was recognized by CD4+ Th cells in the context of HLA-DPB1*0401 and HLA-DQB1*0604. This makes it an excellent candidate for cancer immunotherapy because it is very immunogenic in vivo at least if delivered on DCs (13), and ∼76% of Caucasians express HLA-DPB1*0401, HLA-DPB1*0402, or HLA-DQB1*0604. It is noteworthy that the CD4+ T cell clones obtained from the two vaccinated patients differed not only in their HLA restriction but also recognized different core epitopes within the 16-mer peptide used for vaccination. For instance, T cell clones from patient R15 were stimulated by the original 16-mer peptide and 7 of 12 truncated peptides tested, whereas T cell clones from patient R12 only recognized the 16-mer peptide and 2 other truncated peptides (Fig. 3⇑). Importantly, these T cell clones did not recognize peptide TQHFVQENYLEY (MAGE-3247–258) which has been previously identified as the minimal epitope efficiently recognized by CD4+ T cells (12). These findings suggest that the use of longer peptides for vaccination is advisable because they may induce a broader Th cell response in patients.

The different peptide recognition pattern of the two clones is also interesting from another point of view as it might be one possible explanation for the observed differences in Ag recognition. For instance, clone R15-14 did not recognize peptide KKLLTQHFVQENY, which efficiently stimulated clone R12-57. Assuming that this peptide would be preferentially processed by tumor cells, the failure of clone R15-14 to recognize HLA-matched tumor cells or DCs that had taken up dead or dying tumor cells could be explained. Although this is only speculation, differences in Ag recognition between MAGE-3-specific CD4+ T cell clones have also been reported by others (38).

In conclusion, our data suggest that tumor-specific CD4+ Th1 cells induced in melanoma patients by vaccination with peptide-loaded, monocyte-derived DCs matured by a cytokine mixture containing IL-1β, IL-6, TNF-α, and PGE2 can differ in their HLA restriction, peptide-specificity, and function and there is strong evidence that they should be helpful for antitumor immunity in vivo.

Acknowledgments

We thank S. Emmerling and E. Müller for their excellent technical assistance.

Footnotes

  • ↵1 This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (SCHU 1264/2-1) and the Erlanger Leistungs bezogene Anschubtiman-zierumg und Nachwuchstocrdorung program of the University of Erlangen-Nuremberg, Germany (to E.S.S.), and a Cancer Research Institute Melanoma Initiative Clinical Grant (to G.S.).

  • ↵2 Address correspondence and reprint requests to Dr. Erwin Schultz, Department of Dermatology, University Hospital of Erlangen, Hartmannstraβe 14, D-91052 Erlangen, Germany. E-mail address: erwin.schultz{at}derma.imed.uni-erlangen.de

  • ↵3 Abbreviations used in this paper: MAGE-3, melanoma Ag 3; DC, dendritic cell; FasL, Fas ligand.

  • Received June 17, 2003.
  • Accepted November 5, 2003.

References

  1. ↵
    Van der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. van den Eynde, F. Brasseur, T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51.
    OpenUrlCrossRefPubMed
  2. ↵
    Rosenberg, S. A.. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281.
    OpenUrlCrossRefPubMed
  3. ↵
    Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
    OpenUrlCrossRefPubMed
  4. ↵
    Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
    OpenUrlCrossRefPubMed
  5. ↵
    Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al 1999. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Schuler-Thurner, B., D. Dieckmann, P. Keikavoussi, A. Bender, C. Maczek, H. Jonuleit, C. Roder, I. Haendle, W. Leisgang, R. Dunbar, et al 2000. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 165:3492.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
    OpenUrlCrossRefPubMed
  8. ↵
    Pardoll, D. M.. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
    OpenUrlCrossRefPubMed
  9. ↵
    Toes, R. E., F. Ossendorp, R. Offringa, C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:753.
    OpenUrlFREE Full Text
  10. ↵
    Ossendorp, F.. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Wang, R. F.. 2001. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22:269.
    OpenUrlCrossRefPubMed
  12. ↵
    Schultz, E. S., B. Lethe, C. L. Cambiaso, J. Van Snick, P. Chaux, J. Corthals, C. Heirman, K. Thielemans, T. Boon, P. van der Bruggen. 2000. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 60:6272.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:1279.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Thurner, B., C. Roder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Keikavoussi, E. Kampgen, A. Bender, G. Schuler. 1999. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223:1.
    OpenUrlCrossRefPubMed
  15. ↵
    Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135.
    OpenUrlCrossRefPubMed
  16. ↵
    Tatsumi, T., L. S. Kierstead, E. Ranieri, L. Gesualdo, F. P. Schena, J. H. Finke, R. M. Bukowski, J. Mueller-Berghaus, J. M. Kirkwood, W. W. Kwok, W. J. Storkus. 2002. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB10401+ patients with renal cell carcinoma or melanoma. J. Exp. Med. 196:619.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
    OpenUrlCrossRefPubMed
  18. ↵
    Ridge, J. P.. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474.
    OpenUrlCrossRefPubMed
  19. ↵
    Bennett, S. R.. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
    OpenUrlCrossRefPubMed
  20. ↵
    Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, H. Levitsky. 1998. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188:2357.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Greenberg, P. D.. 1985. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2− T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Qin, Z., T. Blankenstein. 2000. CD4+ T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 12:677.
    OpenUrlCrossRefPubMed
  23. ↵
    Manici, S., T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, M. P. Protti. 1999. Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189:871.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Zarour, H. M., B. Maillere, V. Brusic, K. Coval, E. Williams, S. Pouvelle-Moratille, F. Castelli, S. Land, J. Bennouna, T. Logan, J. M. Kirkwood. 2002. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 62:213.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Takahashi, T., P. B. Chapman, S. Y. Yang, I. Hara, S. Vijayasaradhi, A. N. Houghton. 1995. Reactivity of autologous CD4+ T lymphocytes against human melanoma: evidence for a shared melanoma antigen presented by HLA-DR15. J. Immunol. 154:772.
    OpenUrlAbstract
  26. ↵
    Appay, V., J. J. Zaunders, L. Papagno, J. Sutton, A. Jaramillo, A. Waters, P. Easterbrook, P. Grey, D. Smith, A. J. McMichael, et al 2002. Characterization of CD4+ CTLs ex vivo. J. Immunol. 168:5954.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Williams, N. S., V. H. Engelhard. 1996. Identification of a population of CD4+ CTL that utilizes a perforin-rather than a Fas ligand-dependent cytotoxic mechanism. J. Immunol. 156:153.
    OpenUrlAbstract
  28. ↵
    Echchakir, H., M. Bagot, G. Dorothee, D. Martinvalet, S. Le Gouvello, L. Boumsell, S. Chouaib, A. Bensussan, F. Mami-Chouaib. 2000. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a Fas-independent pathway for specific tumor cell lysis. J. Invest. Dermatol. 115:74.
    OpenUrlCrossRefPubMed
  29. ↵
    Yasukawa, M., H. Ohminami, J. Arai, Y. Kasahara, Y. Ishida, S. Fujita. 2000. Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4+ as well as CD8+ cytotoxic T lymphocytes in humans. Blood 95:2352.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Stalder, T., S. Hahn, P. Erb. 1994. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J. Immunol. 152:1127.
    OpenUrlAbstract
  31. ↵
    Hanabuchi, S., M. Koyanagi, A. Kawasaki, N. Shinohara, A. Matsuzawa, Y. Nishimura, Y. Kobayashi, S. Yonehara, H. Yagita, K. Okumura. 1994. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 91:4930.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Ju, S. T., H. Cui, D. J. Panka, R. Ettinger, A. Marshak-Rothstein. 1994. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc. Natl. Acad. Sci. USA 91:4185.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Thomas, W. D., P. Hersey. 1998. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:2195.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Dorothee, G., I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, F. Mami-Chouaib. 2002. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-α on APO2L/TRAIL expression and mediated cytotoxicity. J. Immunol. 169:809.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Lewinsohn, D. M., T. T. Bement, J. Xu, D. H. Lynch, K. H. Grabstein, S. G. Reed, M. R. Alderson. 1998. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J. Immunol. 160:2374.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Fleischer, B.. 1984. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 308:365.
    OpenUrlCrossRefPubMed
  37. ↵
    Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Kobayashi, H., Y. Song, D. S. Hoon, E. Appella, E. Celis. 2001. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 61:4773.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Kobayashi, H., M. Wood, Y. Song, E. Appella, E. Celis. 2000. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60:5228.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Kobayashi, H., R. Omiya, M. Ruiz, E. Huarte, P. Sarobe, J. J. Lasarte, M. Herraiz, B. Sangro, J. Prieto, F. Borras-Cuesta, E. Celis. 2002. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin. Cancer Res. 8:3219.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Consogno, G., S. Manici, V. Facchinetti, A. Bachi, J. Hammer, B. M. Conti-Fine, C. Rugarli, C. Traversari, M. P. Protti. 2002. Identification of immunodominant regions among promiscuous HLA-DR restricted CD4+ T cell epitopes on the tumor antigen MAGE-3. Blood 101:1038.
    OpenUrlPubMed
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section